The Keio Journal of Medicine
INSTRUCTIONS FOR AUTHORS
Aims and Scope
The Keio Journal of Medicine (KJM) is the peer-reviewed
medical journal of Keio University School of Medicine.
KJM, in publication since 1952, publishes articles focusedon clinical and experimental medicine to support the professional and educational needs of its readership. As an official publication of Keio Medical Society, KJM is indexed in
PubMed, Medline, Index Medicus, Scopus and Web of Science (BIOSIS).
Supporting the medical field at large, we serve as a repository of clinical and experimental information, contributing
as an invaluable resource to physicians, researchers and othermedical professionals around the world. To this end, KJM
welcomes submissions from authors and doctors worldwide.
All articles are freely accessible online at J-stage, Japan’slargest platform for academic journals.
KJM is devoted to publishing original articles, reviews andcase reports in the field of medicine and the life sciences. Reviews are available upon request and at the discretion of the
Editorial Board Members. Clinico-pathological conference
and letters to the editor will also be considered for publication. For more information on the types of articles published,
see the journal’s instruction for authors.
Editorial Information:
KJM endeavors to make initial decisions on manuscripts
within 30 - 45 days after submission, aiming to offer authors
the most expedient form of publication possible. After acceptance, manuscripts are immediately processed and are
published online as advanced publication within approximately average 7 - 14 days. The periodical is issued quarterly:
March, June, September and December.
Online Manuscript Submission
Manuscripts should be submitted via KJM’s online submission and peer review website (known as ScholarOne
Manuscripts) at http://mc.manuscriptcentral.com/kjm.
• Simply log on to ScholarOne Manuscripts and follow the
onscreen instructions for all submissions (you will need toregister before your first submission to KJM).
• For figures, submission of original and editable artwork
files is encouraged. Digital photograph files should have aresolution of at least 300 dpi.
• If you have any technical problems or questions related
to the electronic submission process or uploading yourfiles, please contact our Support Desk. For other inquiries,
please contact our Editorial Office.
ScholarOne Manuscripts Support Desk (Japan)
Phone: +81-3-3910-4517
E-mail: s1-support@kyorin.co.jp
Open weekdays from 09:00 to 17:00 (closed 12:00 to 13:00)
JST

ScholarOne Manuscripts Support Desk (USA)
ScholarOne, Inc., Thomson Reuters
Phone: 434-964-4100/888-503-1050 (U.S.-based numbers)
Open weekdays from 12:00 to 20:30 EST
E-mail: Please send e-mail from “Get Help Now” on the upper right corner of the online submission homepage.
The KJM Editorial Office
Keio University School of Medicine, 35 Shinanomachi,
Shinjuku, Tokyo 160-8582, JAPAN
Phone: +81-3-3353-1211 (Ext. 64023)
Fax: +81-3-3351-3116
E-mail: keio-j-med@imic.or.jp
Prerequisites for Publication
Papers will be received on the understanding that they havenot been published in whole or in part elsewhere.
1. Copyright Transfer
The Editorial Board reserves the right to revise the manuscripts when required. KJM owns all copyright to any work
published in the Journal. Any material submitted, whether
appearing in the journal or not, may not be used, reproduced,
or transmitted without the written consent of KJM.
The Copyright Transfer Statement, which is available at:
http://www.kjm.keio.ac.jp/page/authors_top.html, must be
signed by corresponding author and must be submitted to thejournal’s editorial office by uploading it as a PDF file or byfax (+81-3-3351-3116) at the same time that you submit yourmanuscript via ScholarOne Manuscripts.
IMPORTANT: Upon receipt of the Certification for Manuscript Submission, manuscripts are officially recognized assubmissions.
2. Authorship
Authors should meet all four criteria for authorship listed
in the International Committee of Medical Journal Editors(ICMJE) recommendations (http://www.icmje.org). All authors are expected to take responsibility for the content of themanuscript submitted to KJM. It is the responsibility of alllisted authors of the article to have contributed in a meaningful and identifiable way to the design, analysis, and reportingof the work and to agree and provide final approval for all
aspects of the work. All authors will be contacted by email at
submission to ensure that they are aware of, and approve of,the submission of the manuscript, its content, and its authorship.
3. Conflicts of Interest
KJM’s conflicts of interest policy is compliant with ICMJE
recommendations.
For more information, please see (http://www.icmje.org/
recommendations/browse/roles-and-responsibilities/authorresponsibilities--conflicts-of-interest.html).
Authors must state all possible conflicts of interest in the
manuscript, including financial, consultant, institutional, andhttp://www.kjm.keio.ac.jp

other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be
explicitly stated at the end of the main text before the references (see example below). All relevant conflicts of interestand sources of funding should be included between the text
and references of the manuscript with the heading “Conflictsof Interest.”
For example:“Conflicts of Interest: ‘Author A’ reports grants and non-financial support from ‘Company 1’ during the conduct of thestudy and grants and personal fees from ‘Company 2’ outside
the submitted work. ‘Author B’ has a patent, ‘Patent 1234567,’
licensed to ‘Company 3’ and is President of ‘Foundation X’.
‘Author B’ receives no compensation for this position, but
The Foundation pays expenses for travel to its annual meeting. The remaining authors have disclosed that they do nothave any conflicts of interest.”
Authors who have no conflicts of interest to declare need toinsert the following statement between the text and references:“Conflicts of Interest: The authors have declared that no conflict of interest exists.”
4. Human/Animal Experimental Subjects
When reporting research dealing with any types of datafrom human subjects (both observational studies and interventional studies) or animal subjects, authors should indicate
whether the procedures followed were in accordance with the
ethical standards of the responsible committee, such as theInstitutional Review Board (IRB)/Ethics Committee/Animal
Welfare Committee, along with the IRB approval number.
5. Human Rights Statement
For studies involving human subjects, the following statement should be included in the Materials and Methods section:“Ethical approval: All procedures followed were in accordance with the ethical standards of the responsible committee at which the studies were conducted (IRB approval number XXXXX) and with the Helsinki Declaration of 1964 andlater versions. Informed consent to be included in the study,or the equivalent, was obtained from all patients.”
If authors did not obtain an IRB approval number, an IRB approval form should be submitted with the article and a statement should be inserted in the Materials and Methods section
affirming that IRB/Ethics Committee/Animal Welfare Committee approval has been obtained.
Identifying information of patients or human subjects – including names, initials, addresses, admission dates, hospital numbers, or any other data that could be used to identify
them – should not be published in written descriptions orphotographs unless the information is essential for scientificpurposes, and the patient (or their parent/guardian) has given
written informed consent to publish.
If any identifying information about patients is included in
the article, the following sentence should also be included:“Additional informed consent was obtained from all patientsfor which identifying information is included in this article.”

6. Animal Studies
For studies with animals, include/indicate the following information in the Materials and Methods section. State that all
institutional and national guidelines for the care and use oflaboratory animals were followed and that the studies wereapproved by a research ethics committee at the institution orpractice at which the studies were conducted.
7. Informed Consent
Informed consent for publication of identifiable images
from human research participants (or a parent or legal guardian for participants under the age of 16 years) must be confirmed by a statement attesting that the authors have obtained
consent for publication of the images. If the participant is deceased, consent must be sought from the next of kin of theparticipant. In all such instances, all reasonable measures
must be taken to protect patient anonymity. Black bars overthe eyes are not acceptable means of anonymization. Images
without appropriate consent must not be submitted for publication.
If identifying information about participants is given in anarticle, the following statement should be included in the Materials and Methods section: “Additional informed consent
was obtained from all participants for whom identifying information is included in this article.”
8. Clinical Trial Registration
KJM follows the ICMJE, which uses the World HealthOrganization’s definition (http://www.who.int/ictrp/en) of aclinical trial.
The ICMJE defines a clinical trial as:“Any research study that prospectively assigns human participants or groups of humans to one or more health-related
interventions to evaluate the effects on health outcomes.”
Health-related interventions include any intervention (e.g.,
drugs, surgical procedures, devices, behavioral treatments,
dietary interventions, or process-of-care changes) used tomodify a biomedical or health-related outcome. Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic
measures and adverse events. Purely observational studies(those in which the assignment of the medical intervention
is not at the discretion of the investigator) will not requireregistration.
If a manuscript describes the work or outcomes of a clinical
trial, the trial must be registered at one of the registries thatthe journal deems to be compliant (see below).
Authors must also provide or submit the original protocol
upon request and provide the registration identification number and the URL for the trial’s registry upon submission in
the Materials and Methods section.
Non-exhaustive list of compliant registries:
http://www.clinicaltrials.gov/ (Clinical Trials)
http://isrctn.org (ISRCTN Registry)
http://www.umin.ac.jp/ctr (UMIN Clinical Trials Registry)

http://www.kjm.keio.ac.jp

9. Copyright Permissions
Authors wishing to include figures and/or tables that havealready been published elsewhere are required to obtain permission from the copyright owner(s) (and pay any associated costs) for both the print and online formats. The source
should be given in the article.
Authors wishing to reuse their own work (e.g., figures, tables)that was originally published in KJM do not need to request
permission as long as it is not for commercial use. However,
the reproduced material must be accompanied by a full citation of the original source, and the author is required toclearly state the copyright holder in the figure legend, tablefootnote, etc. as appropriate.
10. Policy on Secondary Publication
A secondary publication of a full-length paper, which is notindexed in Medline, may be considered in our journal only
when the manuscript contains important information that deserves to be disseminated to a significantly different readership from that of the original publication. Further details on
acceptable forms of secondary publication can be found at
http://www.icmje.org. For more information, please contact
our Editorial Office.
11. Accelerated Reviews of Manuscripts
The reviewing of manuscripts by the Editorial Committee may be accelerated on an exceptional basis when urgent
publication is desired. The author must state the specific reasons for the request to accelerate the review process whensubmitting the manuscript via ScholarOne Manuscripts. The
reasons should be described in the Cover Letter box or in an
attached cover letter.
12. Posting preprints on preprint servers
The Keio Journal of Medicine supports the sharing of yourdata on preprint servers such as bioRxiv, medRxiv, PsyArXiv,
and SportRxiv prior to publication. The original manuscript
submitted to The Keio Journal of Medicine may be posted on
preprint servers at any time.
We do, however, ask that you respect the following policies:
1) Authors are required to report their intent to post manuscripts on preprint servers at the time of submission to The
Keio Journal of Medicine.
2) Authors are required to inform the DOI of the final accepted manuscript to relevant preprint servers.

4. Clinico-Pathological Conferences are usually invited by
the editors and educate the reader about rare but clinically important diseases. Readers wish to learn about every facet of thecase presented and not about unrelated material, so avoid extraneous information that has little bearing on the case at hand.
5. Letters to the Editor may deal with material in publishedarticles or they may raise new issues. Short clinical and experimental observations may also be presented as Letters to
the Editor.
Preparation of Manuscripts
Manuscripts should be double-spaced with 3-cm margins
on only one side of the paper.
The title and introduction should be prepared in a way thatreaders outside the field are able to comprehend the aim andsignificance of the study.
It is highly recommended that authors consult with colleagues with different expertise to review the manuscript
before submission to identify terminology and concepts thatmight be difficult for non-specialist readers to understand.
1. Cover Letter As part of the initial submission, the author
must explain the originality or essence of his/her paper ina cover letter. Revised manuscripts should be accompanied
by a cover letter explaining how the manuscript has beenchanged and a separate point-by-point response to reviewers’comments.
2. Title Page The title page should bear the title of the paper
and the name(s) of the author(s), together with the address(es)at which the work was carried out. Please note that the title
should be concise and comprehensible to readers outside thefield. The name, full postal address, and e-mail address ofthe corresponding author who will be responsible for reading
the proofs should be given on the first page. A running title
must also be provided (not exceeding 50 characters including
spaces).

Types of Manuscripts

3. Summary A summary must appear on the second page ofthe paper; it should be no longer than 250 words and should
be a single paragraph. It should state the subject, new findings, and conclusions of the article in generally intelligible
terms. A summary is not required for clinico-pathologicalconferences or letters to the editor.

1. Original Articles are scientific reports of the results oforiginal research in clinical and experimental medicine.
New, significant, innovative, and original findings are suitable as original articles.

4. Keywords Up to five keywords identifying the nature of
the subject matter may be used to alert readers. Keywords
should be listed below the summary. Use terms from the
medical subject headings list of Index Medicus.

2. Review Articles are usually invited by the editors. They
should contain at least 1 figure or table.

5. Text Papers should be written clearly in good scientificEnglish. Avoid laboratory slang and minimize jargon.

3. Case Reports should contain information which significantly advances our knowledge on medical sciences or practice and are to be presented as concisely as possible. The
number of references should be kept to an absolute minimum.

For original articles, the article should follow the usual layout for scientific papers and be as brief as full documentation
allows (rarely exceeding 20 printed pages). The text should
be organized in the following order:

http://www.kjm.keio.ac.jp

(1) Introduction:
The section should contain a clear statement of the purpose of the work, the reasons for undertaking the research, and pertinent background of the study that allows
readers outside the field to understand the purpose andsignificance of the work.
(2) Materials and Methods:
Description of methods should be brief, but with sufficient detail to enable the experiments to be repeated by
the readers. The design of the study or experiments, any
specific procedures used, and statistical analyses must be
described clearly and carefully. References to other papers describing the techniques may be given. The nameand location (city and state/country) of commercial suppliers of uncommon chemicals, reagents, or instruments
should be mentioned.
(3) Results:
The results should be presented concisely. Tables and figures should be used only if they are essential for the comprehension of the data.
(4) Discussion:
The purpose of the discussion is to interpret the results
and to relate them to existing knowledge in the field.
Information already given in the introduction or results
should not be repeated.
For review articles and letters to the editor, appropriate
subheadings should be used.
For case reports, the text may be arranged as follows, or theheadings may be modified as necessary:(1) Introduction(2) Case Presentation(3) Discussion
For Clinico-Pathological conferences, the text should contain the following sections:(1) Introduction:
This should summarize what is about to be presented andthe reasons why the case was chosen. Please prepare thissection in a way that general readers outside the field areable to comprehend the aim and significance of the study.
(2) Case Presentation:
This part contains a succinct narrative of the case itself.
Figures, photographs, and tables with data can be included.
(3) Discussion:
The discussion should be a focused presentation of thedifferential diagnostic procedure and include comments
by guest speakers.
(4) Pathology Presentation:
This part summarizes the pathological findings.
(5) Final Diagnosis:
This should be one sentence giving the final diagnosis.
(6) Key Points:
Authors should include a brief summary of the case (maximum 50 words) composed of a bulleted list of up to four
key points. These should cover what is already known
about the condition, what the current case adds to our experience, and what we should learn from the case.

6. Acknowledgments All acknowledgments, including thoseof financial support, should be given here. Acknowledgmentsof people precede those of financial support. Names of grantsources should be spelled out.
7. References References should be numbered consecutively
in the order of citation in the text. Abbreviations for titles of
medical periodicals should conform to those in the latest edition on Index Medicus. In the reference list, give the namesof all authors. Authors are responsible for the accuracy of thereferences.
(1) Periodicals:
1. Boatman JB, Boucek MM, Rabinovitz MJ: Mitochondrial swelling during cold exposure of the rat and hamster.
Am J Physiol 1962; 202: 1037–1040.
2. Kennedy CR, McCann DC, Campbell MJ, Law CM,
Mullee M, Petrou S, Watkin P, Worsfold S, Yuen HM,
Stevenson J: Language ability after early detection of
permanent childhood hearing impairment. N Engl J Med
2006; 354: 2131–2141.
(2) Books:
1. Irving L: Comparative anatomy and physiology of gas
transport mechanisms. In: Fenn WO, Rahn H, eds, Handbook of Physiology, Washington DC, American Physiological Society, 1964; 177–212.
Only papers that are published or in press may be cited in
the reference list.
8. Tables Tables should be numbered (Arabic numerals) in
the order in which they are referred to in the text. Each tableshould have a brief title, be on a separate page, and be double-spaced throughout. Non-standard abbreviations should
be used sparingly and must be defined in a legend at the bottom of the table. Table citations in the text should be boldface(e.g., Table 1). For table titles, use lower case letters with only
the first letter capitalized.
9. Figures All illustrations (line drawings and photographs)
are classified as figures. Digital photograph files should havea resolution of at least 300 dpi. Figures should be cited in consecutive order in the text. Figure citations in the text should
be boldface. The abbreviation “Fig.” should be used when using parenthesis (e.g., (Fig. 1)), otherwise the word “Figure”
should be spelled out (e.g., Figure 1) throughout the text. If a
figure consists of multiple parts, capital letters (A, B, C, etc.)
should be used to label them (e.g., Fig. 1A). Legends for the
figures should be double-spaced, in numerical order, and on a
separate page. Non-standard abbreviations should be definedin legends. For figure titles, use lower case letters with only
the first letter capitalized.
The magnification of microphotographs should be indicatedin the legends or a bar should be included in the figure to indicate the scale (or both). Lettering of figures requires carefulattention. Illustrations may be submitted in the final size or
larger for reduction by the printer. Symbols and lines should
be chosen to remain legible after the degree of reduction thatwill be used.

http://www.kjm.keio.ac.jp

10. Electronic Supplementary Material Electronic supplementary material will be published in the on-line version
only. It may consist of information that cannot be printed:
animations, video clips, sound recording information thatis more convenient in electronic form: sequences, spectral
data, etc. Please include in each file the following information: article title, journal name, author names; affiliation andemail address of the corresponding author. Please always use
MPEG-1(.mpg) format.
11. Abbreviations, Symbols, and Typesetting Standard abbreviations for certain substances and for units of measurement do not need to be defined. Other abbreviations that areconsidered to be non-standard should be kept to a minimum
and must be spelled out on first usage, followed by the abbreviation in parentheses. Mark gene names for typesetting
in italics to distinguish them from gene products of the sameor similar name, ad hoc designations for genes, gene segments, and gene clusters, families, complexes, or groups. In
general, genotypes should be italicized; phenotypes should
not be italicized. Using italics for emphasis should be avoided
throughout the text.
Publication Fees
For page charges, see the table below (not including tax).
The corresponding author will be invoiced before publication.
Monochrome(yen/page)Color(yen/page)¥ 5,000¥ 55,000

The Journal reserves the right to modify the charges without
prior notification.
Last updated June 25, 2021

http://www.kjm.keio.ac.jp